Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions

SchizophreniaOxidative Stress

Interventions

DRUG

Alpha-lipoic acid

Administration of ALA (100 mg/day) for 4 months, as an adjunct to antipsychotic medication.

DRUG

Placebo Oral Tablet

Administration of placebo, as an adjunct to antipsychotic medication.

Trial Locations (1)

Núcleo de Pesquisa e Desenvolvimento de Medicamentos - UFC, Fortaleza

All Listed Sponsors

collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

lead

Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara

OTHER

NCT03788759 - Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia | Biotech Hunter | Biotech Hunter